---
title: "SSY Group Wins China Approval for Next-Generation Lipid-Lowering Capsule"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292851574.md"
description: "SSY Group (HK:2005) received approval from China’s National Medical Products Administration for its Choline Fenofibrate Sustained-release Capsules. This type 4 chemical drug targets severe hypertriglyceridemia and dyslipidemia, offering advantages over traditional fenofibrate such as reduced organ burden and compatibility with statins. The approval supports SSY Group's strategy to expand in cardiovascular therapeutics and create new revenue opportunities. Analysts maintain a 'Buy' rating with a HK$5.00 price target."
datetime: "2026-07-16T04:37:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292851574.md)
  - [en](https://longbridge.com/en/news/292851574.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292851574.md)
generator: "portal-rs"
---

# SSY Group Wins China Approval for Next-Generation Lipid-Lowering Capsule

SSY Group ( (HK:2005) ) has issued an update.

SSY Group Limited has received approval from China’s National Medical Products Administration to produce and register its Choline Fenofibrate Sustained-release Capsules (135mg), classified as a type 4 chemical drug and recognized as having passed consistency evaluation. The product is designed for adults with severe hypertriglyceridemia, primary hypercholesterolemia or mixed dyslipidemia, positioning the group to expand its presence in next-generation lipid-lowering treatments and potentially strengthen its competitiveness in the high-end cardiovascular therapeutics segment.

Unlike traditional fenofibrate, the choline fenofibrate formulation offers a direct effect, reduced liver and kidney burden, no dietary restrictions, and safe combination with statins, features that may enhance its clinical adoption and differentiate it in the market. The announcement signals ongoing progress in SSY Group’s product pipeline, informing shareholders and potential investors of a new revenue opportunity and underscoring the company’s strategy to build a stronger portfolio in specialized cardiovascular care within China’s regulated drug market.

The most recent analyst rating on (HK:2005) stock is a Buy  
 with a HK$5.00 price target.  
 To see the full list of analyst forecasts on SSY Group stock,  
 see the HK:2005 Stock Forecast page. 

**More about SSY Group**

SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs for the treatment of chronic and metabolic diseases. The company targets the Chinese healthcare market, supplying prescription therapies that address cardiovascular and lipid-related conditions through its portfolio of advanced formulations.

**Average Trading Volume:** 5,629,541

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$6.96B

### Related Stocks

- [02005.HK](https://longbridge.com/en/quote/02005.HK.md)

## Related News & Research

- [SSY Group Wins China Approval for New Letermovir Injection](https://longbridge.com/en/news/298535677.md)
- [Huatai Securities Sticks to Their Buy Rating for SSY Group (LJUIF)](https://longbridge.com/en/news/297389381.md)
- [FDA Approves Tablet Form of Zanubrutinib for All Approved Indications](https://longbridge.com/en/news/298434766.md)
- [Handa Oncology Receives FDA Final Approval for OMCAZIO(TM) (cabozantinib) Capsules](https://longbridge.com/en/news/298728074.md)
- [SSY Group wins China NMPA approval for choline fenofibrate sustained-release capsules](https://longbridge.com/en/news/292848979.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**